Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term

Company Overview - United Therapeutics Corporation is based in Silver Spring, MD and markets four medicines in the United States for treating pulmonary arterial hypertension (PAH): Remodulin, Orenitram, Tyvaso, and Adcirca [7] Earnings Estimates - Seven analysts have revised their earnings estimates upwards for fiscal 2024, with the Zacks Consensus Estimate increasing by $0.85 to $24.62 per share [8] - United Therapeutics boasts an average earnings surprise of 12.4% [8] Investment Ratings - United Therapeutics has a Zacks Rank of 3 (Hold) and a Value Style Score of B, indicating attractive valuation metrics such as a forward P/E ratio of 11.23 [20] - The company also has a VGM Score of A, suggesting strong overall performance potential [20][21] Investment Strategy - To maximize investment returns, it is recommended to consider stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [18] - Stocks with a 3 (Hold) rank should also have Style Scores of A or B to ensure upside potential [18]